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92 Session: Disease & Treatmentandmineralized nodules, and the highest levels ofmRNA expression of osteogenesis-
related genes collagen-1, ALPand BMP-2 in the osteoblasts. The in vivo studies found
that the rats in the 1 h group, 1.5 h group and 2 h group had significantly higher bone
mineral densities (BMD) than those of the control group, and the highest BMD was
obtained in the 1.5h group. The rats in the 0.5 h group and 3h group were not statis-
tically different in the BMD values with the control. The mechanical tests and bone
morphometrical analysis results revealed a similar tendency. The serum osteocalcin
level was the highest while the TRAP5b level was the lowest in the 1.5 h group.
Discussion and Conclusion: Our data has demonstrated that SEMF treatment at
1.5 h per day has the strongest osteogenic activity than other duration times in
the rat primary osteoblasts. The in vivo studies provided further supports that
SEMF treatment at 1.5 h per day increased the BMD of growing rats to the greatest
extent compared to other durations within 3 h. Our study suggests that the oste-
ogenic effects of SEMFs are duration-dependent and 1.5h per day is the optimal
duration for improving peak bone mass and may be used for the prevention and
treatment of osteoporosis.
http://dx.doi.org/10.1016/j.jot.2016.06.073147
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Objective: Long non-coding RNAs (lncRNAs), extensively transcribed from the
mammalian genome, have gained widespread attention in recent years. They serve
as important and powerful regulators of various biological activities and play crit-
ical roles in a variety of disease progression including differentiation. More and
more emerging evidence has demonstrated that some lncRNAs play important reg-
ulatory roles in osteoblast differentiation of MSCs, suggesting a potential therapeu-
tic strategy for bone formation. The lncRNA H19, one of the most well-known
imprinted genes, is located on human chromosome 11 and it is transcribed only
from the maternally inherited allele. Recent researches have highlighted H19 as
an active modulator in embryonic placental growth and skeletal muscle differen-
tiation. However, unfortunately, the role of H19 in osteoblast differentiation is
largely unknown and its function remains to be characterised.
Methods: Cultures of bone marrow-derived MSCs were established from a healthy
donor. The gene encoding human H19 was amplified and cloned into a pBABE retro-
virus vector. The H19 overexpression stable hMSCs were generated using retro-
virus-mediated gene delivery method as previously described. Osteogenic
differentiation was induced according to the published protocols and examined
by using ALP activity assay, Alizarin Red Staining, and marker genes expression.
Furthermore, the in vivo effect of H19 on osteogenesis was evaluated by ectopic
bone formation carried out in nude mice. Using bioinformatics tool, the candidate
miRNAs targeting were screened out and the direct interaction between H19 and
miRNA was identified by using a luciferase activity assay.
Results: In the present study, lncRNA H19 was found to be upregulated during
osteogenesis in human mesenchymal stem cells. Stable expression of H19 signifi-
cantly accelerated in vivo and in vitro osteoblast differentiation. Meanwhile, by
using bioinformatic investigations and RNA immunoprecipitation assays combined
with luciferase reporter assays, we successfully demonstrated that H19 functioned
as a miRNA sponge for miR-141 and miR-22, both of which were negative regulators
of osteogenesis. Further investigations revealed that H19 antagonized the endog-
enous functions of these two miRNAs and led to the de-repression of their shared
target gene b-catenin, which eventually activated the Wnt/b-catenin pathway and
hence potentiated osteogenesis. In addition, we also identified a novel regulatory
feedback loop between H19 and its encoded miR-675-5p. miR-675-5p was found to
directly target H19 and counteracted osteoblast differentiation.
Conclusion: Taken together, these findings indicate that the lncRNA H19 modu-
lates the Wnt/b-catenin pathway by acting as a competing endogenous RNA, which
may help to develop a novel therapeutic strategy for promoting fracture healing
and bone regeneration.
http://dx.doi.org/10.1016/j.jot.2016.06.074148
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Objective: Animal models of osteoarthritis (OA) are of considerable importance in
elucidating the underlying mechanisms of joint damage and providing proof of
concept in the development of pharmacological and biological agents that may
modify structural damage in the OA joint. Currently, there is still a lack of an
appropriate small animal model of OA which represents the underlying mecha-
nisms. Since transforming growth factor-beta/Smad (TGF-b/Smad) signalling
pathway has been identified as a key pathway in osteoarthritis (OA) initiation
and progression, we then hypothesise that animal models of OA could be estab-
lished by the interruption of TGF-b/Smad signalling. This study aims to investigate
the role of Smad7, one of the TGF-b/Smad signalling pathway inhibitors, in the
initiation and progression of OA, then further to evaluate whether Smad7 partial
knockout mouse is a good animal model of OA.
Methods: The genetically engineered Smad7DE1 (KO) and wild type (WT) mice (nZ
15) at the age of 6, 12, or 24 months were terminated for histological analysis. The
anterior cruciate ligament transection (ACLT) or sham operation were performed
in both the 6-month old Smad7 KO (nZ16) and WT (nZ16) mice. Histology, immu-
nohistochemistry (IHC), and micro-computed tomography (CT) analysis were per-
formed to determine the pathological changes in the articular cartilage and
subchondral bone after 6 weeks. The knee joints were harvested and subject to
histology and IHC examinations.
Results: Histological staining showed that there was no significant difference in
the articular cartilage between Smad7 KO and WT mice at 6, 12 or 24 months
old. However, cartilage hypertrophic markers (MMP13 and Col X) were significantly
upregulated in the intact Smad7 KO mice at 6-months, indicating Smad7 is essen-
tial for cartilage homeostasis. In the ACLT surgery model, six weeks after surgery,
typical OA phenotype characterised by cartilage destruction, osteophyte forma-
tion, and synovium inflammation were all found in the Smad7 KO mice, where
only mild degenerative changes were seen in the wild type control mice. Results
of Micro-CT showed total bone volume and bone mineral density of subchondral
bone were significantly increased in the Smad7 KO mice comparing to the wild
type mice after ACLT, indicating a bone hardening in the subchondral bone area.
Results of IHC also showed osteogenic marker Osterix was significantly upregulated
in the Smad7 KO mice after ACLT, suggesting enhanced bone formation.
Conclusion: Smad7 plays an important role in cartilage homeostasis. Lack of
Smad7 may contribute to OA intiation. Smad7 KO mice are susceptible to OA pro-
gression under mechanical instability conditions. Smad7 KO mice may be used as
an animal model of osteoarthritis to further study the underlying mechanisms.
http://dx.doi.org/10.1016/j.jot.2016.06.075152
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Background: Osteoarthritis (OA) is the most common degenerative joint disorder.
Inflammatory cytokines play an important role in OA progression. Previous studies
have demonstrated that ginsenoside Rb1 would prevent inflammation and
apoptosis in chondrocytes. However, we did not find any animal study that re-
ported the effect of Rb1 on attenuation of the severity of osteoarthritis.
Objective: In this study, we used a rat anterior cruciate ligament transection plus
medial meniscus resection (ACLT+MMx) model of OA and cell model to investigate
whether administration of ginsenoside Rb1 may attenuate the progression of
arthritis.
Methods: In the in vivo study, the 16-week-old male Sprague-Dawley rats were
divided into three groups: Group 1: sham control group; Group 2: Rb1-treated
Session: Disease & Treatment 93group; Group 3: OA Group. In group 2e3, osteoarthritis was induced in the right
knee joint with ACLT+MMx in rats. Group 2 received continuous infusion of the gin-
senoside Rb1 via an osmotic mini-pump, implanted subcutaneously. At four weeks
after treatment, the rat was sacrificed. Interleukin-1 beta (IL-1b) level was evalu-
ated by ELISA; cartilage damage was assessed via histology (Safranin-O/fast green
stain) and immunohistochemistry (MMP13, Col X). In the cell study, C5.18 (Rat
chondrocyte cell line) was used. The effect on Rb1 of IL-1b- induced MMP13 or
Col X expression level in C5.18 cells was investigated.
Results: In the in vivo study, characteristics of OAwere present in the OA group, con-
trary to the Rb1 treatment group where, in general, less severe damage occurred:
initially, IL-1b level was significantly decreased; then, cartilage degeneration was
attenuated, by lower histologic damage scores and the percentage of MMP13 or
Col X positive chondrocytes. In the cell study, the results showed that Rb1treatment
would relieve the MMP13 or Col X expression in C5.18 cells in IL-1b induction.
Conclusion: In the present study, we demonstrated that Rb1 can attenuate the
progression or severity of arthritis via reducing the inflammation level.
http://dx.doi.org/10.1016/j.jot.2016.06.076163
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Background: Recent studies suggest association between ABO blood group and
inflammation, which was crucial in the pathological process of primary knee oste-
oarthritis. This study was aimed to investigate whether ABO blood group was asso-
ciated with primary knee osteoarthritis.
Methods: We performed a retrospective review of patients of primary knee oste-
oarthritis as the case group, and a random sampling of healthy blood donors as the
control group. The severity of knee osteoarthritis at the first outpatient visit was
evaluated by the Kellgren/Lawrence scoring system. Further study was performed
to investigate the expression of blood group antigens in synovial tissue of the knee
in both cases and controls.
Results: 1126 cases and 30299 controls were involved. Logistic regression revealed
that AB blood group was a risk factor of primary knee osteoarthritis (PZ0.025 and
0.048 for univariate and multivariate analysis, respectively), independent of age
(PZ0.973) and sex (PZ0.520). Patients of blood group AB had a higher K/L score
(PZ0.017). Immunohistochemical study indicated association between LeY antigen
and primary knee osteoarthritis (PZ0.029).
Discussions and Conclusions: This study suggested that blood group AB was asso-
ciated with primary knee osteoarthritis, as well as its radiological severity. Further
study indicated that LeY antigen, which was related to blood group, was associated
with primary knee osteoarthritis.
http://dx.doi.org/10.1016/j.jot.2016.06.077169
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Introduction: Disruption of the balance between bone formation and resorption
results in loss of bone mass and causes bone diseases such as osteoporosis. Current
therapies for osteoporosis are limited to antiresorptive agents, while bone diseases
due to reduced osteoblast activity, such as senile osteoporosis, urgently require
targeted treatment and novel strategies to promote bone formation. mTORC1
has emerged as a critical regulator of bone formation and is therefore a potential
target in the development of novel bone-promoting therapeutics. Identifying the
detailed function of mTORC1 in bone formation and clarifying the underlying
mechanisms may uncover useful therapeutic targets.
Subjects and Methods: We treated osteoblasts and mice with rapamycin (the
mTORC1-specific inhibitor) and established conditional Tsc1 knockout cell and
mouse models (with activated mTORC1). We detected the proliferation rate and
differentiation potential of osteoblasts with impaired or activated mTORC1 and
explored the regulatory mechanism responsible.
Results: mTORC1 is activated during preosteoblast proliferation but is suppressed
during their differentiation. Inactivation of mTORC1 prevents preosteoblast prolif-
eration but enhances their differentiation in vitro and in vivo. mTORC1 activation
in preosteoblasts produces immature woven bone in mice due to excess prolifera-
tion and impaired differentiation. mTORC1 inhibits Runx2 expression by activating
Notch signalling in preosteoblasts. Preosteoblasts with hyperactive mTORC1 re-ac-
quired the capacity to fully differentiate and mature when subjected to inhibition
of the Notch pathway.Discussion and Conclusions: mTORC1 signalling has emerged as a critical regulator
of bone formation; however, results from in vitro and in vivo studies on the func-
tion of mTORC1 in osteoblast lineage are inconsistent. Using mTORC1 specific in-
hibitor and conditional knockout cell and mouse models, we elucidated the role
of mTORC1 in osteoblast formation. Here, we report that activation of mTORC1
is required for preosteoblast proliferation; however, inactivation of mTORC1 is
essential for their differentiation and maturation. Mechanistically, mTORC1 pre-
vented osteoblast maturation through activation of the STAT3/p63/Jagged/Notch
pathway and down-regulation of Runx2. In conclusion, this study clarified the po-
tential role of mTORC1 signalling in the regulation of preosteoblast proliferation
and differentiation and identified Notch signalling and Runx2 as critical down-
stream mediators. Pharmaceutical coordination of the pathways and agents in pre-
osteoblasts may be beneficial in bone formation.
http://dx.doi.org/10.1016/j.jot.2016.06.078174
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Introduction: Previously, we reported that sufficient lymphatic drainage was
favourable for the treatment of Rheumatoid arthritis (RA) and treatment targeting
joint lymphatic drainage function contributed to the improvement of chronic
inflammation of joints. JuanBi Tang (JBT), a Chinese patent medicine, has been
widely used for the treatment of RA in China, which can relieve symptoms of
arthritis and activate joint function of patients. The aim of this study is to inves-
tigate whether JBT could attenuate inflammation and promote lymphatic drainage
function and lymphangiogenesis of TNF-Tg mice.
Subjects and Methods: Three-month old TNF-Tg mice and WT littermates were
used. (1) The effect of JBTon lymphatic drainage function was detected with Indoc-
yanine green near-infrared (ICG-NIR) lymphatic imaging system. (2) The effect of
JBT on ankle joints inflammation were assessed by haematoxylin and eosin (H&E)
staining, Alcian blue/orange G (ABHO) staining, and tartrate resistant acid phospha-
tase (TRAP) staining. (3) The effect of JBT on lymphangiogenesis at inflammatory
ankle joints was detected by using anti-LYVE-1 and anti-podoplanin antibodies for
double immunofluorescence staining. (4) The effect of JBT on lymphangiogenesis
was determined by a zebrafish screening system. (5) The effect of JBT on iNOS
expression andNOproduction of lymphatic endothelial cells (LECs)were also tested.
Results: Decreased clearance and pulse from ICG-NIR detection indicated TNF-tg
mice lymph function is impaired, but it was rescued by JBT (p<0.05). According
to HE staining of ankle sections, JBT (1.2kg/L) could increase TNF-tg mice astraga-
lus bone area (1.540.78mm2) in contrast to saline mice (0.750.24 mm2,
p<0.05), almost equal to WT mice (1.580.75 mm2, p>0.05). The inflammation
area around the astragalus bone of TNF-tg mice (1.070.44 mm2) increased
compared with the WT littermates (0, p < 0.05). JBT could reduce the inflamma-
tion area (1.770.44mm2, p<0.05). As to Alcian blue/orange G (ABHO) stain, carti-
lage area of the astragalus bone (1.770.44mm2, p<0.05) increased more than 20-
fold in the JBT group compared with the saline group. JBT promotes lymphangio-
genesis in the ankle joint of TNF-Tg mice. JBT could also promote the formation of
the lymphatic thoracic duct of zebrafish (48h and 72h, p<0.05). In addition, JBT
blocked iNOS expression and NO production of LECs.
Conclusion: JBT decreases synovial inflammation, bone erosion and cartilage
erosion, and promotes lymphatic drainage function and lymphangiogenesis in
TNF-Tg mice. JBT is a promising agent for treating Rheumatoid arthritis and pro-
moting the lymphatic drainage function might be one of its mechanisms.
http://dx.doi.org/10.1016/j.jot.2016.06.079228
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Objective: Bone fracture non-union is a major clinical challenge in orthopaedic
practice. In addition to surgical intervention and autologous bone grafts, bone
